Eiurosurv. Interim 2024/25 influenza vaccine effectiveness: eight European studies, September 2024 to January 2025

[tetano]

• Angela MC Rose[SUP]1,2,3[/SUP] , Héloïse Lucaccioni[SUP]1,2[/SUP] , Kimberly Marsh[SUP]4[/SUP] , Freja Kirsebom[SUP]5[/SUP] , Heather Whitaker[SUP]5[/SUP] , Hanne-Dorthe Emborg[SUP]6[/SUP] , Amanda Bolt Botnen[SUP]7[/SUP] , Mark G O’Doherty[SUP]8[/SUP] , Francisco Pozo[SUP]9,10[/SUP] , Safraj Shahul Hameed[SUP]4[/SUP] , Nick Andrews[SUP]5[/SUP] , Mark Hamilton[SUP]4[/SUP] , Ramona Trebbien[SUP]7[/SUP] , Karina Lauenborg Møller[SUP]11[/SUP] , Diogo FP Marques[SUP]1[/SUP] , Siobhan Murphy[SUP]8[/SUP] , Ross McQueenie[SUP]4[/SUP] , Jamie Lopez-Bernal[SUP]5[/SUP] , Simon Cottrell[SUP]12[/SUP] , Magda Bucholc[SUP]8[/SUP] , Esther Kissling[SUP]1,3[/SUP] , European IVE group[SUP]13[/SUP]

The 2024/25 influenza season in Europe is currently characterised by co-circulation of influenza A(H1N1)pdm09, A(H3N2) and B/Victoria viruses, with influenza A(H1N1)pdm09 predominating. Interim vaccine effectiveness (VE) estimates from eight European studies (17 countries) indicate an all-age influenza A VE of 32–53% in primary care and 33–56% in hospital settings, with some signals of lower VE by subtype and higher VE against influenza B (≥ 58% across settings). Where feasible, influenza vaccination should be encouraged and other prevention measures strengthened.
​
https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2025.30.7.2500102